|
1
|
Kantari C and Walczak H: Caspase-8 and
Bid: Caught in the act between death receptors and mitochondria.
Biochim Biophys Acta. 1813:558–563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu Y, Bertram CC, Shi Q and Zinkel SS:
Proapoptotic Bid mediates the Atr-directed DNA damage response to
replicative stress. Cell Death Differ. 18:841–852. 2011. View Article : Google Scholar :
|
|
3
|
Song G, Chen GG, Chau DKF, Miao J and Lai
PBS: Bid exhibits S phase checkpoint activation and plays a
pro-apoptotic role in response to etoposide-induced DNA damage in
hepatocellular carcinoma cells. Apoptosis. 13:693–701. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsuno T, Mejido J, Zhao T, Phillips T,
Myers TG, Bekisz J and Zoon KC: BID is a critical factor
controlling cell viability regulated by IFN-α. J Immunother.
35:23–31. 2012. View Article : Google Scholar
|
|
5
|
Goncharenko-Khaider N, Lane D, Matte I,
Rancourt C and Piche A: The inhibition of Bid expression by Akt
leads to resistance to TRAIL-induced apoptosis in ovarian cancer
cells. Oncogene. 29:5523–5536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miao J, Chen GG, Chun SY, Yun JP, Chak EC,
Ho RL and Lai PB: Adenovirus-mediated tBid overexpression results
in therapeutic effects on p53-resistant hepatocellular carcinoma.
Int J Cancer. 119:1985–1993. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fukazawa T, Walter B and Owen-Schaub LB:
Adenoviral Bid overexpression induces caspase-dependent cleavage of
truncated Bid and p53-independent apoptosis in human non-small cell
lung cancers. J Biol Chem. 278:25428–25434. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Dai C, Li J, Wang W and Song G:
Bid-overexpression regulates proliferation and phosphorylation of
Akt and MAPKs in response to etoposide-induced DNA damage in
hepatocellular carcinoma cells. Onco Targets Ther. 5:279–286.
2012.PubMed/NCBI
|
|
9
|
Orzechowska EJ, Kozlowska E, Czubaty A,
Kozlowski P, Staron K and Trzcinska-Danielewicz J: Controlled
delivery of BID protein fused with TAT peptide sensitizes cancer
cells to apoptosis. BMC Cancer. 14:7712014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tacara O, Sriamornsak P and Dass CR:
Doxorubicin: an update on anticancer molecular action, toxicity and
novel drug delivery systems. J Pharm Pharmacol. 65:157–170. 2012.
View Article : Google Scholar
|
|
11
|
Yang F, Teves SS, Kemp CJ and Henikoff S:
Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys
Acta. 1845.84–89. 2014.
|
|
12
|
Leung KL and Wang TT: Differential effects
of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in
human breast cancer cell line MCF-7. Basic Cancer Res Treat.
55:73–83. 1999. View Article : Google Scholar
|
|
13
|
Watanabe M, Naraba H, Sakyo T and Kitagawa
T: DNA damage-induced modulation of GLUT3 expression is mediated
through p53-independent extracellular signal-regulated kinase
signaling in HeLa cells. Mol Cancer Res. 8:1547–1557. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kelly MM, Hoel BD and Voelkel-Johnson C:
Doxorubicin pretreatment sensitizes prostate cancer cell lines to
TRAIL induced apoptosis which correlates with the loss of c-FLIP
expression. Cancer Biol Ther. 1:520–527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kang J, Bu J, Hao Y and Chen F: Subtoxic
concentration of doxorubicin enhances TRAIL-induced apoptosis in
human prostate cancer cell line LNCaP. Prostate Cancer Prostatic
Dis. 8:274–279. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sánchez C, Mendoza P, Contreras HR,
Vergara J, McCubrey JA, Huidobro C and Castellón EA: Expression of
multidrug resistance proteins in prostate cancer is related with
cell sensitivity to chemotherapeutic drugs. Prostate. 69:1448–1459.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong FC, Woo CC, Hsu A, Kwong B and Tan
BK: The anticancer activities of Vernonia amygdalina extract in
human breast cancer cell lines are mediated through
caspase-dependent and p53-independent pathways. PLoS One.
8:e780212013. View Article : Google Scholar
|
|
18
|
Desagher S, Osen-Sand A, Montessuit S,
Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B and
Martinou JC: Phosphorylation of Bid by casein kinases I and II
regulates its cleavage by caspase 8. Mol Cell. 8:601–611. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee SJ, Hwang SO, Noh EJ, Kim DU, Nam M,
Kim JH, Nam JH and Hoe KL: Transactivation of bad by
vorinostat-induced acetylated p53 enhances doxorubicin-induced
cytotoxicity in cervical cancer cells. Exp Mol Med. 46:e762014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Jin TG, Yang H, DeWolf WC,
Khosravi-Far R and Olumi AF: Persistent c-FLIP(L) expression is
necessary and sufficient to maintain resistance to tumor necrosis
factor-related apoptosis-inducing ligand-mediated apoptosis in
prostate cancer. Cancer Res. 64:7086–7091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Z, Zhang Y, Mehta SK, Pierson DL, Wu H
and Rohde LH: Expression profile of apoptosis related genes and
radio-sensitivity of prostate cancer cells. J Radiat Res.
52:743–751. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hait WN and Yang JM: The individualization
of cancer therapy: the unexpected role of p53. Trans Am Clin
Climatol Assoc. 117:85–101. 2006.
|
|
23
|
Bien S, Rimmbach C, Neumann H, Niessen J,
Reimer E, Ritter CA, Rosskopf D, Cinatl J, Michaelis M, Schroeder
HW and Kroemer HK: Doxorubicin-induced cell death requires
cathepsin B in HeLa cells. Biochem Pharmacol. 80:1466–1477. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Howells CC, Baumann WT, Samuels DC and
Finkielstein CV: The Bcl-2-associated death promoter (BAD) lowers
the threshold at which the Bcl-2-interacting domain death agonist
(BID) triggers mitochondria disintegration. J Theor Biol.
271:114–123. 2011. View Article : Google Scholar
|
